{
    "clinical_study": {
        "@rank": "48430", 
        "arm_group": [
            {
                "arm_group_label": "Immediate treatment group", 
                "arm_group_type": "Other", 
                "description": "This group will receive vitamin D supplementation for the first 6 months, then will be monitored off vitamin D for the next 6 months."
            }, 
            {
                "arm_group_label": "Delayed treatment group", 
                "arm_group_type": "Other", 
                "description": "This group will be monitored for the first 6 months, and then will be given vitamin D for the next 6 months."
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators are conducting a prospective cross-over study to evaluate the effects of\n      vitamin D supplementation on diabetes control and the pro-inflammatory markers involved in\n      microvascular complications in adolescents with Type 1 Diabetes.  The investigators expect\n      to see a significant improvement in glycemic control and a reduction of serum\n      pro-inflammatory markers in adolescents with Type 1 Diabetes and vitamin D deficiency or\n      insufficiency, who are treated with vitamin D."
        }, 
        "brief_title": "The Effects of Vitamin D on Glycemic Control and Proinflammatory Markers in Adolescents With T1DM", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Type 1 Diabetes", 
            "Vitamin D Deficiency/Insufficiency"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Vitamin D Deficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Between 13 to 21 years of age, with at least Tanner stage 4 sexual maturity for males\n             or post-menarchal females, and T1DM for at least 1 year.  To ensure that inclusion\n             criteria for sexual maturity are met, a physical exam for research purposes will be\n             performed.\n\n          2. HbA1c between 7 to 9%\n\n          3. Adequate renal function (serum creatinine < 1.5 mg/dL in males and < 1.2 mg/dL in\n             females) and adequate liver function (AST and ALT < 2.5 times the upper limit of\n             normal)\n\n          4. Vitamin D insufficiency or deficiency (25-OH vit D level < 30ng/mL) which will be\n             determined on initial screening labs after consenting subjects.\n\n        Exclusion Criteria:\n\n          1. Less than 13 or greater than 21 years of age\n\n          2. Less than Tanner stage 4 sexual maturity for males or pre-menarche\n\n          3. HbA1c less than 7% or greater than 9%\n\n          4. T1DM for less than 1 year\n\n          5. Vitamin D sufficient (25-OH vit D level > 30 ng/mL)\n\n          6. Currently taking any medication that can interfere with vitamin D synthesis or\n             metabolism, including but not limited to Orlistat, Phenobarbital, Dilantin,\n             Anti-tuberculosis drugs\n\n          7. Currently taking any medication other than insulin that alters blood glucose levels,\n             including but not limited to systemic glucocorticoids\n\n          8. Inadequate renal function (serum creatinine > 1.5mg/dL in males and > 1.2mg/dL in\n             females) or inadequate liver function (AST and ALT > 2.5 times the upper limit of\n             normal)\n\n          9. Evidence of malabsorption or short gut."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697228", 
            "org_study_id": "11-00352"
        }, 
        "intervention": {
            "arm_group_label": [
                "Immediate treatment group", 
                "Delayed treatment group"
            ], 
            "intervention_name": "Vitamin D", 
            "intervention_type": "Dietary Supplement"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetes", 
            "Vitamin D", 
            "Proinflammatory markers"
        ], 
        "lastchanged_date": "October 1, 2012", 
        "location": {
            "contact": {
                "email": "eshih@chla.usc.edu", 
                "last_name": "Erin Shih, D.O.", 
                "phone": "323-361-8705"
            }, 
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90027"
                }, 
                "name": "Children's Hospital Los Angeles"
            }, 
            "investigator": [
                {
                    "last_name": "Erin Shih, D.O.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Roshanak Monzavi, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Steven Mittelman, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Pisit Pitukcheewanont, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effects of Vitamin D Supplementation on Glycemic Control and Proinflammatory Markers Involved in Microvascular Complications in Adolescents With Type 1 Diabetes.", 
        "overall_contact": {
            "email": "eshih@chla.usc.edu", 
            "last_name": "Erin Shih, D.O.", 
            "phone": "(323) 361-8705"
        }, 
        "overall_official": {
            "affiliation": "Children's Hospital Los Angeles", 
            "last_name": "Roshanak Monzavi, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint in this study will be the difference in change in Hemoglobin A1c between the treatment and non-treatment periods (6 months)", 
            "measure": "Hemoglobin A1c", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697228"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Children's Hospital Los Angeles", 
            "investigator_full_name": "Roshanak Monzavi MD", 
            "investigator_title": "Assistant Professor, Center for Endocrinology, Diabetes, and Metabolism", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in pro-inflammatory markers (CRP, IL-6, TNF-\u03b1) between treatment and non-treatment periods", 
                "measure": "Pro-inflammatory markers", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Correlation between change in vitamin D levels and circulating pro-inflammatory markers, including CRP, IL-6, and TNF-\u03b1", 
                "measure": "Vitamin D level and proinflammatory markers", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Correlation between the change of vitamin D levels on insulin requirements", 
                "measure": "Vitamin D levels on insulin requirements", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Correlation between the change in vitamin D level in the blood and change in HbA1c", 
                "measure": "Vitamin D level and HbA1c", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Comparison of baseline differences between vitamin D deficient/insufficient subjects and vitamin D sufficient subjects (including pro-inflammatory markers, HbA1c and total daily insulin requirements", 
                "measure": "Baseline differences between vitamin D deficient & sufficient subjects", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }
        ], 
        "source": "Children's Hospital Los Angeles", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Children's Hospital Los Angeles", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}